Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medigene ( (DE:MDG1) ) has issued an update.
Medigene AG has revised its financial guidance for 2024, reducing its expected revenue from EUR 9-11 million to EUR 7-9 million due to the anticipated delay of a EUR 2 million milestone payment. Despite this adjustment, the company maintains its cash runway guidance into July 2025 and its R&D expense projections, highlighting its confidence in future income streams and continued investment in research and development.
More about Medigene
Medigene AG is an oncology platform company that specializes in the development of T cell receptor (TCR)-guided therapies for cancer treatment. It is listed on the Frankfurt Stock Exchange and operates in the Prime Standard market segment in Germany.
YTD Price Performance: -61.59%
Average Trading Volume: 845
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €8.11M
For detailed information about MDG1 stock, go to TipRanks’ Stock Analysis page.
